The following is a summary of “Response to initial treatment with glucocorticoids in TAFRO syndrome and implications for ...

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

Muscle mass plays a crucial role in overall health, strength, and metabolic function, making its regulation essential for maintaining quality of life. A re | Cell And Molecular Biology ...

Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.

While Roche’s Gazyva has been on the market for a dozen years and has won four approvals from the FDA, it is making a late ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...